

Task Force on Repurposing of Drugs (TFORD) for COVID-19

Patent status in India: by GNANLEX

Ruxolitinib

A. Active patents

S.no.	Title	Assignee	Patent details	Type of patent	Remarks
1.	Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors	Incyte Holdings Corporation	Grant no: IN269841 Priority date: 12/12/2005 Grant date:10/11/2015 Expected expiry date:12/12/2026 Form 27: Worked in India	Product patent	Patent Barrier up to 12/12/2026. Licensing options may be explored

B. Pending applications

S.no.	Title	Assignee	Application details	Type of patent	Remarks
1.	Deuterated Derivatives Of Ruxolitinib	Concert Pharmaceuticals Inc.	App no: 10670/DELNP/2014 Priority date 15/12/2014 Status: Reply to FER was submitted on 25/10/2019	Derivative	No patent barrier even if granted
2.	Sustained- Release Dosage Forms Of Ruxolitinib	Incyte Holdings Corporation	App no. 5153/DELNP/2015 Filing/Priority date : 12/06/2015 Status: Reply to FER was submitted on 31/10/2019	Formulation	Patent Barrier, if granted. Licensing options may be explored unless worked around
3.	Novel Polymorphs Of (R)-3-(4-(7h-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1h-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile Phosphate	Msn Laboratories Private Limited	App no: 5225/CHE/2014 Filing/Priority date 15/12/2014 Status: Application has been published	Polymorph patent	No patent barrier even if granted
4.	Process For The Preparation Of Amorphous (R)-3-(4-(7h-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1h-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile Phosphate	Msn Laboratories Private Limited	App no: 2369/CHE/2015 Filing/Priority date 11/05/2015 Status: Application has been published	Process	
5.	Preparation Of Ruxolitinib And Its Intermediates	Dr. Reddy's Laboratories Limited	App no: 3623/CHE/2015 Filing/Priority date 15/07/2015 Status: Application has been published	Process	No patent barrier even if granted
6.	Improved Process For The Preparation Of (R)-3-(4-(7h-	Msn Laboratories Private Limited	App no: 5639/CHE/2015 Filing/Priority date	Process	No patent barrier even if

Commissioned by



Task Force on Repurposing of Drugs (TFORD) for COVID-19**Patent status in India: by GNANLEX**

	Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1h-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile Phosphate		20/10/2015 Status: Application has been published		granted
--	--	--	--	--	---------

C. Expired/Lapsed applications - None**Disclaimer:**

Search results are up to 11th April 2020

GNANLex's Opinion / Report as hereinabove is to the best of our knowledge, true and accurate as of the date compiled based on available information. However, no guarantee is made as to its accuracy, reliability or completeness. The final user is expected to assume sole liability for any patent infringement that occurs by following our recommendations or using the information given. Before using, user should determine the suitability of the information for his intended use. The risk and liability, if any, in connection therewith, is solely that of the user.

Commissioned by